इस एपिसोड के बारे में

अंग्रेज़ी
संयुक्त राज्य अमरीका

अनुलिपि 🔗

पिछले एपिसोड्स खोजें

Taylor & Francis के पिछले एपिसोड खोजें।

इस पॉडकास्ट के अन्य एपिसोड

Over the past two decades, HER2-positive breast cancer has undergone a dramatic transformation in oncology. In this interview, Cristina Saura (Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Spain) reflects on witnessing this evolution firsthand, from the introduction of …
First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group
In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.
In this interview, Imogen Locke (The Royal Marsden NHS Foundation Trust, UK) discusses the evolving role of stereotactic ablative radiotherapy (SABR) in oligometastatic and oligoprogressive breast cancer. Locke explains the distinction between these two clinical scenarios, how timing and patient s…
अस्वीकरण: इस पृष्ठ पर एम्बेडेड पॉडकास्ट और कलाकृति Taylor & Francis Group से हैं, जो इसके मालिक की संपत्ति है और Listen Notes, Inc. से संबद्ध या समर्थित नहीं है।